Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click for why LLY growth remains strong.

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to-earnings-to-growth (PEG) ratio of 0.4. PEGs below 1 are generally considered undervalued, so on that basis, the stock is very inexpensive.

Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now she fears a deal struck between CVS Health Corp. and Novo Nordisk A/S will undo all that progress.

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.